Open AccessKonsekwencje nowej ustawy refundacyjnej dla pacjentów i płatnika
Author(s) -
Józef Haczyński,
Zofia Skrzypczak
Publication year - 2016
Publication title -
internetowy kwartalnik antymonopolowy i regulacyjny
Language(s) - English
Resource type - Journals
eISSN - 2299-5749
pISSN - 2299-8837
DOI - 10.7172/2299-5749.ikar.8.5.7
Subject(s) - reimbursement , medical prescription , family medicine , value (mathematics) , business , public funding , medicine , actuarial science , political science , public administration , nursing , law , health care , machine learning , computer science
The Act on the Reimbursement of Medicines, Foodstuffs Intended for Particular Nutritional Uses and Medical Devices came into force on 1 January 2012. Its purpose was to transform the Polish medicine reimbursement so that the available public funds corresponded as closely as possible to the current social needs in the supply of refunded products. The consequence of the new reimbursement act – experienced painfully by patients - was a decrease in the share of reimbursement (and thus increase in patients’ contribution) in the value of the purchased medicine on prescription (Rx).